Skip to Content

About us

Meet our team

Dedicated professionals driving our success

Dr. C. Thomas Dow

Founder and Managing Director

C. Thomas Dow, MD is an ophthalmologist and physician‑researcher; having a background in medical microbiology, his research work explores the potential role of Mycobacterium avium subspecies paratuberculosis (MAP) in human autoimmune and inflammatory disease. A long‑time senior partner at the Chippewa Valley Eye Clinic and former volunteer faculty member at the University of Wisconsin–Madison, Dr. Dow has published and lectured on MAP as a possible environmental driver of Crohn’s disease, Type 1 diabetes, and thyroid autoimmunity. His research emphasizes microbial pathogenesis, host–pathogen interactions, and translational implications for chronic disease.

Daniel V. Szemis

President

Daniel V. Szemis is the Founder and President of the Early Learning Opportunity Group, a nonprofit organization established in 2020 to support children from under‑resourced families by strengthening early‑stage learning environments. Before launching the organization, he spent 32 years in investment management, serving as an analyst and portfolio manager at Prudential Insurance Company, Merrill Lynch, and Chilton Investment Company.  Dan earned his MBA from Rutgers Graduate School of Management and completed his undergraduate studies at Virginia Tech.

Dan joined forces with Tom as the President of MapFast, LLC in 2026 to help organize and fund the effort to bring this important testing capability* to market.

Michael T. Collins, DVM, PhD, DACVM

Scientific Advisor

Michael T. Collins, DVM, PhD, DACVM is Professor Emeritus in the School of Veterinary Medicine at the University of Wisconsin–Madison and a leading authority on Johne’s disease and Mycobacterium avium subspecies paratuberculosis (MAP) in ruminants. A board‑certified veterinary microbiologist, Dr. Collins built and directed one of the foremost diagnostic and research programs for MAP infection, helping to define best practices for herd testing, control, and eradication worldwide. His work has guided veterinarians, producers, and regulators in understanding MAP epidemiology, improving diagnostic accuracy, and reducing the burden of chronic enteric disease in dairy and beef cattle.

Mark Boyle

Strategic Business Advisor

Accomplished, results-oriented senior business executive with demonstrated success commercializing in-vitro diagnostic products for global healthcare markets.  Mark played a key role in the launch and commercialization of the QuantiFERON-TB test, leading global market development with Cellestis and QIAGEN to create a $100 million global business franchise.